IDEAS home Printed from https://ideas.repec.org/p/ohe/briefg/000438.html
   My bibliography  Save this paper

From Efficacy to Cost-Effectiveness

Author

Listed:
  • Michael F. Drummond;Adrian Towse

Abstract

This OHE Briefing summarises the presentations and discussion at the session on 'Efficacy to cost-effectiveness' at the Conference of the International Society for Technology Assessment in Health Care (ISTAHC) in Barcelona on 26 May 1997. The participants were: Professor Michael Drummond, Director of the Centre for Health Economics, University of York, UK Dr Kevin Schulman, Director of the Clinical Economics Research Unit, Georgetown University Medical Center, USA Professor Milton Weinstein, Henry J. Kaiser Professor of Health Policy and Management, Harvard School of Public Health, USA Professor Bengt Jonsson, Stockholm School of Economics, Sweden.

Suggested Citation

  • Michael F. Drummond;Adrian Towse, 1998. "From Efficacy to Cost-Effectiveness," Briefing 000438, Office of Health Economics.
    • Handle: RePEc:ohe:briefg:000438
    as

    Download full text from publisher

    File URL: https://www.ohe.org/publications/efficacy-cost-effectiveness/attachment-241-1998_from_efficacy_towse/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Darrin Baines;Keith Tolley;David Whynes, 1997. "Prescribing, Budgets and Fundholding in General Practice," Series on Health 000426, Office of Health Economics.
    2. Adrian Towse, 1997. "Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?," Monograph 000423, Office of Health Economics.
    3. Weinstein, M.C. & Coxson, P.G. & Williams, L.W. & Pass, T.M. & Stason, W.B. & Goldman, L., 1987. "Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model," American Journal of Public Health, American Public Health Association, vol. 77(11), pages 1417-1426.
    4. Peter West, 1998. "Managed Care - A Model for the UK?," Monograph 000440, Office of Health Economics.
    5. Office of Health Economics, 1997. "The Pros and Cons of Modelling in Economic Evaluation," Briefing 000428, Office of Health Economics.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Nick Marchant, 1998. "Tuberculosis," Series on Health 000445, Office of Health Economics.
    2. Office of Health Economics, 1998. "Controlling NHS Expenditure: The Impact of Labour’s NHS White Papers," Monograph 000435, Office of Health Economics.
    3. Hannah Kettler, 1998. "Competition through Innovation, Innovation through Competition," Monograph 000434, Office of Health Economics.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Clive Pritchard, 1998. "Trends in Economic Evaluation," Briefing 000444, Office of Health Economics.
    2. Rasstrigin, M. & Kitaev, A. & Pleshackova, E., 2023. "Forecasting spending on orphan diseases to maintain the long-run financial sustainability of healthcare system," Journal of the New Economic Association, New Economic Association, vol. 59(2), pages 120-141.
    3. William S. Weintraub & Samuel S. Gidding, 2016. "PCSK9 Inhibitors: A Technology Worth Paying For?," PharmacoEconomics, Springer, vol. 34(3), pages 217-220, March.
    4. Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette, 2006. "Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada," PharmacoEconomics, Springer, vol. 24(8), pages 815-830, August.
    5. Paul Tappenden & James Chilcott, 2014. "Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models," PharmacoEconomics, Springer, vol. 32(10), pages 967-979, October.
    6. Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-357, October.
    7. Office of Health Economics, 1998. "Controlling NHS Expenditure: The Impact of Labour’s NHS White Papers," Monograph 000435, Office of Health Economics.
    8. Yizhe Xu & Tom H. Greene & Adam P. Bress & Brian C. Sauer & Brandon K. Bellows & Yue Zhang & William S. Weintraub & Andrew E. Moran & Jincheng Shen, 2022. "Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective," Biometrics, The International Biometric Society, vol. 78(1), pages 337-351, March.
    9. Hugh S.E. Gravelle, 1998. "Ex post Value Reimbursement for Pharmaceuticals," Medical Decision Making, , vol. 18(2_suppl), pages 27-38, April.
    10. Mark Roberts & Louise B. Russell & A. David Paltiel & Michael Chambers & Phil McEwan & Murray Krahn, 2012. "Conceptualizing a Model," Medical Decision Making, , vol. 32(5), pages 678-689, September.
    11. Gary A. Zarkin & Laura J. Dunlap & Katherine A. Hicks & Daniel Mamo, 2005. "Benefits and costs of methadone treatment: results from a lifetime simulation model," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1133-1150, November.
    12. Meltzer, David, 1997. "Accounting for future costs in medical cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 16(1), pages 33-64, February.
    13. Bob J. H. van Kempen & Bart S. Ferket & Albert Hofman & Sandra Spronk & Ewout Steyerberg & M. G. Myriam Hunink, 2012. "Do Different Methods of Modeling Statin Treatment Effectiveness Influence the Optimal Decision?," Medical Decision Making, , vol. 32(3), pages 507-516, May.
    14. K Cooper & S C Brailsford & R Davies, 2007. "Choice of modelling technique for evaluating health care interventions," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 58(2), pages 168-176, February.
    15. Alexey Vedev & Mikhail Khromov, 2015. "Methodology of Compiling Sectoral Financial Balances in the National Economy," Working Papers 120, Gaidar Institute for Economic Policy, revised 2015.
    16. Salkeld, Glenn & Phongsavan, Philayrath & Oldenburg, Brian & Johannesson, Magnus & Convery, Paula & Graham-Clarke, Peita & Walker, Sheila & Shaw, John, 1997. "The cost-effectiveness of a cardiovascular risk reduction program in general practice," Health Policy, Elsevier, vol. 41(2), pages 105-119, August.
    17. Tekeshe A Mekonnen & Michelle C Odden & Pamela G Coxson & David Guzman & James Lightwood & Y Claire Wang & Kirsten Bibbins-Domingo, 2013. "Health Benefits of Reducing Sugar-Sweetened Beverage Intake in High Risk Populations of California: Results from the Cardiovascular Disease (CVD) Policy Model," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-9, December.
    18. Karen T. Hicklin & Julie S. Ivy & James R. Wilson & Fay Cobb Payton & Meera Viswanathan & Evan R. Myers, 2019. "Simulation model of the relationship between cesarean section rates and labor duration," Health Care Management Science, Springer, vol. 22(4), pages 635-657, December.
    19. Davies, Ruth & Roderick, Paul & Raftery, James, 2003. "The evaluation of disease prevention and treatment using simulation models," European Journal of Operational Research, Elsevier, vol. 150(1), pages 53-66, October.
    20. K. Cooper & S. Brailsford & R. Davies & J. Raftery, 2006. "A review of health care models for coronary heart disease interventions," Health Care Management Science, Springer, vol. 9(4), pages 311-324, November.

    More about this item

    Keywords

    From Efficacy to Cost-Effectiveness;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:briefg:000438. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Publications Manager (email available below). General contact details of provider: https://edirc.repec.org/data/ohecouk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.